rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IVA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Inventiva at guggenheim healthcare conference: lanifibranor nears key readout
      Nov 9Investing.comIVA
      Inventiva (IVA) vs. CRSP and MDGL: Can Lanifibranor’s Phase 3 Trial Unlock 62% Upside?
      Oct 28Yahoo FinanceIVA
      Inventiva Stock: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout

      Inventiva's substantial MASH market opportunity hinges on clinical differentiation and adoption among currently untreated patients. Read more on IVA stock here.

      Oct 14Seeking AlphaIVA
      3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
      Oct 10Yahoo FinanceAAPGIVA
      Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026

      Preclinical data showed that balanced PPARα, PPARδ and PPARγ activation by lanifibranor affects complementary pathways across multiple hepatic cell populations involved in fibrosis in MASH pathogenesisPreclinical data and Phase 2b clinical results showed lanifibranor improved liver sinusoidal endothelial cell alterations and was associated with changes in intrahepatic vascular abnormalities across multiple stages of diseaseAnalysis of plasma cell-free DNA (cfDNA) identified coordinated epigeneti

      Oct 6Yahoo FinanceIVA
      Inventiva (IVA): How Much Is One Make-or-Break Readout Really Worth?

      Inventiva (NASDAQ:IVA) presents a high-stakes clinical binary play, anchored by a cash runway that extends only into Q2 2027 against a €69.5 million first-half net loss. With no commercial products generating revenue, its long-term fundamental story hinges entirely on de-risking its lead asset to capture a portion of an estimated $15 billion MASH market by […]

      Oct 4Yahoo FinanceIVA
      Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
      Oct 4Yahoo FinanceIVA
      Truist Raises Price Target on Inventiva to $18 From $13, Keeps Buy Rating
      Oct 2Yahoo FinanceIVA
      Analysts Are Bullish on These Healthcare Stocks: Pharming Group (PHAR), Inventiva (IVA)

      Detailed price information for Inventiva S.A. ADR (IVA-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailIVAPHAR
      Inventiva (IVA) Receives a Rating Update from a Top Analyst

      Detailed price information for Inventiva S.A. ADR (IVA-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailIVA
      Inventiva at Stifel cardiometabolic forum: lanifibranor nears key test
      Sep 30Investing.comIVASF
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF), Adagene (ADAG) and Inventiva (IVA)

      Tipranks Press Release.

      Sep 30The Globe and MailADAGIVA
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Inventiva S.A. ADR (IVA-Q) from The Globe and Mail including charting and trades.

      Sep 30The Globe and MailIVA
      Inventiva (IVA) Q2 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Sep 29The Globe and MailIVA
      Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Vail Resorts

      U.S. futures mixed as Vail Resorts fell after a Q4 loss miss despite beating sales estimates; several stocks also declined premarket.

      Sep 29BenzingaIVAOVIDMTNNIO
      Truist reiterates Buy on Inventiva stock ahead of phase 3 data
      Sep 28Investing.comIVATFC
      Inventiva SA (IVEVF) (H1 2026) Earnings Call Highlights: Lanifibranor Nears Phase 3 Readout ...
      Sep 28Yahoo FinanceIVA
      Inventiva Q2 Earnings Call Highlights

      Inventiva (NASDAQ:IVA) said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth quarter of 2026, after the last patient completed the study’s 72-week visit earlier this month. Chie

      Sep 28Yahoo FinanceIVA
      Earnings call transcript: Inventiva tops Q2 2026 estimates as investors stay cautious By Investing.com
      Sep 28Investing.comIVA
      Inventiva H1 2026 Earnings Call: Complete Transcript - Inventiva (NASDAQ:IVA)

      On Monday, Inventiva (NASDAQ:IVA) discussed quarterly financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and

      Sep 28BenzingaIVA
      Earnings Scheduled For September 28, 2026 - Kandi Technologies Group (NASDAQ:KNDI), Inventiva (NASDAQ:IVA

      Companies Reporting Before The Bell • Kandi Technologies Gr (NASDAQ:KNDI) is likely to report earnings for its first quarter. • Inventiva (NASDAQ:IVA) is expected to report quarterly loss at $0.20 per share on revenue

      Sep 28BenzingaADXNIVAKNDI
      Inventiva earnings beat by $0.16, revenue topped estimates
      Sep 28Investing.comIVA
      Inventiva H1 Loss Narrows

      Inventiva (IVA) reported a H1 net loss Monday of 0.25 euros ($0.28) per diluted share, narrowing fro

      Sep 28Yahoo FinanceIVA
      Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update

      Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits1 as of June 30, 2026Cash runway guidance remains unchanged from July 30, 20262Topline results of the Phase 3 NATiV3 clinical trial are expected in the fourth quarter of 2026Key highlights from the first half of 2026 and recent Company updatesManagement to host webcast today at 8:00 AM ET to discuss first-half 2026 financial results Daix (France), New York (New York, United States), September 28, 2026 – Inventiva

      Sep 28Yahoo FinanceIVA
      Earnings Scheduled For September 25, 2026 - Tamboran Resources (NYSE:TBN), Inventiva (NASDAQ:IVA)

      Companies Reporting Before The Bell • Tamboran Resources (NYSE:TBN) is estimated to report quarterly loss at $0.30 per share on revenue of $3.82 million. Companies Reporting After The Bell • Inventiva (NASDAQ:IVA) is

      Sep 25BenzingaIVATBN
      Stifel reiterates Buy on Inventiva stock, $15 target on MASH drug
      Sep 23Investing.comIVASF
      Analysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Envista Holdings (NVST) and Inventiva (IVA)

      Detailed price information for Surgery Partners CS (SGRY-Q) from The Globe and Mail including charting and trades.

      Sep 19The Globe and MailIVASGRYNVST
      Stifel reiterates Buy on Inventiva stock ahead of trial data
      Sep 18Investing.comIVASF
      Piper Sandler reiterates Inventiva stock rating on trial confidence
      Sep 16Investing.comIVA
      Guggenheim Sticks to Its Buy Rating for Inventiva (IVA)

      Tipranks Press Release.

      Sep 16The Globe and MailIVA
      Inventiva: A Sub-$1 Billion Bet On A Multi-Billion-Dollar MASH Drug (NASDAQ:IVA)
      Sep 16Seeking AlphaIVA
      Guggenheim raises Inventiva stock price target on trial outlook
      Sep 15Investing.comIVA
      Inventiva to Present Multiple Abstracts at Paris MASH 2026

      Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic profile and cardiovascular risk factors in patients with MASH with or without type 2 diabetesPreclinical data further characterize lanifibranor’s balanced pan-PPAR pharmacology and support a differentiated fluid and cardiac profile relative to TZDs and dual PPARα/γ agonists Daix (France), New York (New York, United States), September 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clin

      Sep 8Yahoo FinanceIVA
      Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH

      Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohortTopline results of NATiV3 expected in Q4 2026September investor conference participation and timing of H1 2026 financial results update Daix (France), New York (New York, United States), September 2nd, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of

      Sep 2Yahoo FinanceIVA
      Chris Benecchi Named Inventiva’s New Chief Operating Officer

      By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company). Mr. Benecchi will lead the company’s operational side as Inventiva comes close to its NATiV3 Phase 3 study results of lanifibranor in MASH, expected for […] The post Chris Benecchi Named Inventiva’s New Chief Operating Officer appeared first on ExecEdge.

      Aug 31Yahoo FinanceIVA
      Inventiva Appoints Chris Benecchi as Chief Operating Officer

      Daix (France), New York City (New York, United States), August 31, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Chris Benecchi as Chief Operating Officer. A proven biopharmaceutical leader with extensive experience in building organizations, preparing medicin

      Aug 31Yahoo FinanceIVA
      Inventiva Names Chris Benecchi COO

      Inventiva (IVA) said late Monday it appointed Chris Benecchi as chief operating officer. Benecchi

      Aug 31Yahoo FinanceIVA

      This is the newest page. Registered accounts read further back.